GALDERMA GROUP AG (GALDY) Income Statement
GALDY 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsGALDY revenue and net income
Where GALDY's revenue goes
2025Each bar shows an amount and its share of revenue. GALDY kept 11.7% of revenue as net income.
GALDY profit margins
GALDY growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +18.0% | +11.1% | — | — |
| Gross profit | +17.0% | +11.1% | — | — |
| Operating income | +29.2% | +29.2% | — | — |
| Net income | +165.4% | — | — | — |
| EPS (diluted) | +169.1% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
GALDY income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $5.24B | $4.44B | $4.12B | $3.82B | $3.44B |
| Cost of revenue | $1.63B | $1.35B | $1.23B | $1.19B | $1.03B |
| Gross profit | $3.61B | $3.08B | $2.88B | $2.63B | $2.41B |
| Research & development | $245.0M | $260.0M | $287.0M | $315.9M | $342.6M |
| Sales, general & admin | $2.37B | $2.05B | $1.89B | $1.82B | $1.63B |
| Total operating expenses | $4.37B | $3.76B | $3.51B | $3.42B | $3.09B |
| Operating income | $876.0M | $678.0M | $611.0M | $406.0M | $357.2M |
| Interest income | $13.0M | $12.0M | $6.0M | $0 | $0 |
| Interest expense | $175.0M | $356.0M | $564.0M | $398.4M | $352.7M |
| Income before taxes | $638.0M | $310.0M | $11.0M | −$51.9M | −$79.7M |
| Net income | $613.0M | $231.0M | −$57.0M | −$98.5M | −$154.3M |
| EBITDA | $1.14B | $959.0M | $851.0M | $624.2M | — |
| EPS (diluted) | $2.61 | $0.97 | −$0.24 | — | — |
| Gross margin | 68.9% | 69.5% | 70.1% | 68.8% | 70.0% |
| Operating margin | 16.7% | 15.3% | 14.8% | 10.6% | 10.4% |
| Net margin | 11.7% | 5.2% | −1.4% | −2.6% | −4.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in GALDY's financial statements (latest annual report filed —); data from EODHD. Sales, general & administrative expenses include sales and marketing.
GALDY financial results
In fiscal year 2025 (ended December 31, 2025), GALDERMA GROUP reported revenue of $5.2 billion, up 18.0% from the year before. It had net income of $613.0 million (up 165.4%), a net profit margin of 11.7%. Diluted earnings per share came to $2.61.
See the GALDY stock overview for the latest quote and news, or the GALDY chart for price history and technical indicators.
GALDY income statement FAQ
What is GALDERMA GROUP's annual revenue?
GALDERMA GROUP reported total revenue of $5.2 billion for fiscal year 2025, which ended on December 31, 2025. That was up 18.0% from $4.4 billion the previous year.
Is GALDERMA GROUP profitable?
Yes. GALDERMA GROUP reported net income of $613.0 million in fiscal 2025, a net profit margin of 11.7%; its operating margin was 16.7%.
What is GALDERMA GROUP's gross margin?
GALDERMA GROUP's gross margin was 68.9% in fiscal 2025: for every $100 of revenue, GALDERMA GROUP kept $69 after the direct cost of its products and services.
How much does GALDERMA GROUP spend on research and development?
GALDERMA GROUP spent $245.0 million on research and development in fiscal 2025, 4.7% of revenue.
What are GALDERMA GROUP's earnings per share?
GALDERMA GROUP earned $2.61 per diluted share in fiscal 2025, compared with $0.97 a year earlier.
When does GALDERMA GROUP's fiscal year end?
GALDERMA GROUP's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025.